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Abstract 
Background: Although the efficacy of tacrolimus for inducing remission of refractory 
ulcerative colitis (UC) is established, its efficacy for maintaining remission of UC has 
not been evaluated.  
Aim: The aim of this study was to evaluate the efficacy of tacrolimus compared with 
thiopurines for maintaining remission in patients with refractory UC. 
Methods: 24 UC patients treated with tacrolimus and 34 treated with thiopurines to 
maintain remission were enrolled as the tacrolimus group and the thiopurine group, 
respectively. In the tacrolimus group, 82.8% of the patients were treated with 
tacrolimus for induction of the remission, while 70% of the patients in the thiopurine 
group were induced remission with either corticosteroid or cytaheresis. Proportions of 
patients who kept steroid-free remission between the tacrolimus group and the 
thiopurine group were compared. Maintenance of remission using tacrolimus or 
thiopurines was defined as no need for other therapies other than aminosalicylates 
without relapse for at least 3 months. Secondary, to determine whether the response to 
thiopurines affects the long-term efficacy of tacrolimus maintenance therapy, the 
overall cumulative relapse-free survival based on the Kaplan-Meier method was 
estimated in thiopurine-naive or thiopurine-intolerant patients and thiopurine-refractory 
ones in the tacrolimus group. 
Results: Remission was successfully maintained in 17 patients (70.8%) of the 
tacrolimus group, and 28 patients (82.4%) of the thiopurine group. The overall 
cumulative relapse-free survival of thiopurine-naive or thiopurine-intolerant patients in 
the tacrolimus group was similar to that in the thiopurine group, and significantly 
higher than that of thiopurine-refractory patients in the tacrolimus group. 
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Conclusions: Maintenance therapy with tacrolimus for patients with UC could be 
considered an alternative to thiopurine therapy. 
Key words: ulcerative colitis, tacrolimus, thiopurines, remission maintenance therapy 
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Introduction 
Ulcerative colitis (UC) is an idiopathic, chronic, and inflammatory disorder 
characterized by diarrhea, rectal bleeding, abdominal pain, fever, anemia, and body 
weight loss.1 Corticosteroid (CS) therapy is used for patients with UC who do not 
respond to aminosalicylates or those with a severe attack.1,2 Although most patients 
with UC initially respond to CS, approximately 20% of patients with UC become 
steroid-dependent within 1 year after initiating CS therapy.3 CS is not used as 
maintenance therapy for patients with UC due to undesirable side effects such as 
opportunistic infections, diabetes mellitus, osteoporosis, etc.4 Therefore, steroid-free 
remission is an important issue for patients with UC. 
Tacrolimus is effective for patients with UC refractory to or dependent on CS, and is 
usually used as a rescue and bridging therapy before initiating azathioprine (AZA) or 
6-mercaptopurine (6-MP) therapy.5-11 Several studies have reported the long-term 
outcomes after tacrolimus therapy for the induction of remission6-9; in all of these case 
series, however, patients received maintenance therapy with other agents, including 
thiopurines, and infliximab after the induction of clinical remission. To our knowledge, 
except for a couple of case reports,6,12 there are no reports on the effect of tacrolimus as 
maintenance therapy for patients with refractory UC. Here we evaluated the efficacy of 
tacrolimus therapy for maintaining remission in patients with refractory UC in 
comparison with thiopurines, currently the most widely used treatment to maintain 
steroid-free remission in patients with refractory UC.1,2
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Patients and Methods 
Patients 
Between April 2001 and October 2009, 42 patients with UC who were resistant to or 
could not be treated with conventional therapy were treated with tacrolimus and 29 
(69.0%) achieved clinical remission. Of those, 23 patients received tacrolimus 
subsequently for the maintenance of remission. In addition, one patient who failed 
tacrolimus therapy for inducing remission was maintained remission with tacrolimus 
after the induction of remission by inflixmab These 24 patients with UC who were 
treated with tacrolimus to maintain remission after achieving remission were enrolled in 
this retrospective, observational, single-center study (tacrolimus group). To compare 
the effect of tacrolimus for maintaining remission of UC, 34 patients who were 
administered thiopurines to maintain remission during the same period were enrolled as 
the thiopurine group. 
In addition, tacrolimus group was divided into two subgroups according to the response 
to thiopurines; i.e., thiopurine-refractory tacrolimus group (nine patients did not have a 
clinical response to thiopurines or relapsed during thiopurine therapy prior to tacrolimus 
administration) and thiopurine-naive or thiopurine-intolerant tacrolimus group (three 
patients discontinued thiopurine treatment because of adverse effects and 12 patients 
had not received thiopurines before tacrolimus therapy). Flow chart of the patients in 
different groups and subgroups was shown in Figure 1.  
This study was reviewed and approved by the Institutional Review Board of Kyoto 
University. Patients were informed about the potential risks and benefits of tacrolimus 
therapy and provided written consent to its use. In all cases, the diagnosis was 
established according to standardized criteria by prior clinical assessment, radiology, 
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endoscopy, and histology. 
Definition of Response 
Disease activity was measured using a modified Truelove Witts severity index 
(MTWSI)13; details are shown in Table 1. Clinical remission was retrospectively 
defined as an estimated MTWSI score 4 or less. Relapse was defined as an increase in 
the MTWSI score to 5 or higher with additional therapies required. To remove the 
influence of other drugs as much as possible when comparing the efficacy of tacrolimus 
and thiopurines for steroid-free remission, maintenance of remission was defined as no 
need for concomitant treatment other than aminosalicylates and topical steroid therapy 
in addition to tacrolimus or thiopurines without relapse for at least 3 months.  
Patients were classified as steroid-resistant or steroid-dependent in accordance with the 
previously published definition of Ogata et al.5  
Treatment 
Tacrolimus was administered in its oral formulation. Dosage was adjusted to produce 
trough tacrolimus whole-blood levels of 10 to 15 ng/ml to induce remission. After 
inducing clinical remission, tacrolimus whole-blood trough concentrations were 
maintained at a lower level, between 5 and 10 ng/ml.9 The initial dose of tacrolimus 
was 0.1 mg/kg body weight/day. The mean doses of tacrolimus for inducing and 
maintaining remission were 7.7 mg/day (range: 2.0-12.0 mg/day) and 5.7 mg/day 
(range: 2.0-10.0 mg/day), respectively. 
For thiopurine maintenance therapy, the dose of AZA or 6-MP was adapted to achieve 
white blood cell counts between 3000 and 5000 per microliter or 6-thioguanine 
nucleotide concentrations between 250 and 500 pmol/8 x 108 red blood cells. 
Twenty-four and 10 patients were treated with AZA and 6-MP, respectively. The mean 
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initial doses of AZA and 6-MP were 30.5mg/day (range: 25-100 mg/day) and 
13.3mg/day (range: 5-30 mg/day), respectively. The mean doses of AZA and 6-MP for 
the remission phase were 53.0mg/day (range: 25-100 mg/day) and 25.0mg/day (range: 
5-40 mg/day), respectively. 
Assessment and statistics 
The primary endpoint of this study was the proportion of patients in whom remission 
was successfully maintained. Secondary endpoints included relapse-free survival and 
treatment safety. 
Proportions between groups were compared by Fisher’s exact test and continuous 
variables were compared by Mann–Whitney U-test. Relapse-free survival was assessed 
using the Kaplan-Meier method. Relapse-free survival of patients who could not 
maintain remission without concomitant therapies other than aminosalicylates and 
topical steroid therapy was set as 0 month. A p-value of less than 0.05 was considered 




Baseline characteristics of the patients in each group and subgroup of the tacrolimus 
group are shown in Table 2 and Table 3, respectively. Except for treatment duration, 
these baseline characteristics of the tacrolimus group were similar to those of thiopurine 
group (Table 2).  
All patients in the tacrolimus group were treated with aminosalicylates. Four patients 
(16.7%) were steroid resistant, 17 patients (70.8%) were steroid dependent, and the 
remaining 3 patients (12.5%) had not been treated with CS. Two patients had received 
infliximab for the induction of remission. No other patients had been treated with 
biologics before tacrolimus maintenance therapy. 
Therapies for the induction of remission that preceded remission maintenance therapy 
are summarized in Table 4. In tacrolimus group, three patients received two courses of 
tacrolimus maintenance therapy and one patient received three treatment courses, and in 
thiopurine group, six patients received two courses of thiopurine maintenance therapy.  
Therefore, total 29 and 40 remission induction therapies were performed prior to 
remission maintenance therapy in tacrolimus and thiopurine group, respectively. 
Maintenance of remission 
In tacrolimus group, remission ratio at 3 and 6 months was 70.8% (17 of 24 patients) 
and 54.2% (13 of 24 patients), respectively. In thiopurine group, remission ratio at 3 
and 6 months was 82.4% (28 of 34 patients) and 73.5% (25 of 34 patients), respectively. 
Proportions of patients who were stayed in remission at 3 and 6 months were not 
statistically different between the two groups (p=0.3494 and 0.1647, respectively; 
Fisher’s exact test). The mean durations of steroid-free remission in the tacrolimus 
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group and the thiopurine group were 9.2 months (range: 0-50.7 months) and 14.0 
months (range: 0-51.6 months), respectively. There was no statistical difference 
between the two groups again (p=0.1114; Mann–Whitney U-test). 
Although there was no significant difference between the two groups, the duration of 
remission in the tacrolimus group tended to be shorter than that in thiopurine group. 
Therefore, to determine whether the response to thiopurine therapy affects the 
long-term efficacy of tacrolimus maintenance therapy, the overall cumulative 
relapse-free survival based on the Kaplan-Meier method was estimated in the 
thiopurine-naive or thiopurine-intolerant tacrolimus group and the thiopurine-refractory 
tacrolimus group. Relapse-free survival in patients in the thiopurine-naive or 
thiopurine-intolerant tacrolimus group was comparable to that in the thiopurine group 
(p = 0.5594; log-rank test) and was significantly higher than that in the 
thiopurine-refractory tacrolimus group (p = 0.0104; log-rank test; Figure 2.)  
Adverse Effects 
The frequency of adverse events during tacrolimus therapy is shown in Table 5. 
Tacrolimus withdrawal was necessary in 4 patients (16.7%). 1 patient (4.2%) contracted 
bacterial pneumonia. He had received a combination of tacrolimus and AZA and 
recovered with antibiotic administration and discontinuation of the tacrolimus and AZA. 
A temporary rise in serum creatinine levels above 1.3 mg/dl occurred in 4 patients 
(16.7%). In 3 cases, tacrolimus withdrawal was necessary and serum creatinine levels 
normalized after discontinuation. In the other case, renal function normalized with dose 
reduction of tacrolimus. 
The thiopurines were discontinued due to side effects in 5 (14.7%) of 34 patients 
undergoing thiopurine maintenance therapy. Of those, 1 patient (2.9%) contracted 
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bacterial pneumonia as described above, 1 patient (2.9%) developed leukopenia, 1 
patient (2.9%) developed pancreatitis, and 2 patients (5.9%) experienced nausea. 
Herpes progenitalis (2.9%, n=1) and mild leukopenias (5.9%, n=2) were also observed.  
All of the patients in both groups recovered with conventional therapy. There was no 
mortality in either of the groups. 
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Discussion 
The findings of the present study demonstrated that the effects of tacrolimus as 
maintenance therapy in thiopurine-naive or thiopurine-intolerant patients with UC are 
comparable to those of thiopurines. To our knowledge, this is the first study to show 
that tacrolimus therapy is valuable for maintaining remission in patients with refractory 
UC in comparison with thiopurine therapy. 
First, we investigated the efficacy of thiopurines for maintaining remission in patients 
with refractory UC enrolled in this study. Our study showed that the proportions of UC 
patients maintaining steroid-free remission with thiopurines at 1 year and 3 years were 
59.2% and 36.5%, respectively (Figure 2). In a prospective, observational cohort study 
by Chebli et al., 14 the proportion of patients with steroid-dependent UC who received 
AZA for 3 years and remained in steroid-free remission was 45% and 57.5% on an 
intention-to-treat basis and per protocol basis, respectively. Fraser et al.15 reviewed the 
clinical notes of 622 patients with inflammatory bowel disease (IBD; 272 Crohn’s 
disease, 346 UC, and 4 indeterminate colitis) who were treated with AZA to maintain 
remission and demonstrated that the relapse-free rate based on a Cox regression 
analysis was 63% at 60 months. Although the relapse-free rate in the later study seems 
to be higher than that in thiopurine therapy in a previous study and in the present study, 
patients who received AZA for less than 3 months were excluded in the study by Fraser 
et al., whereas all patients who were administered thiopurines were enrolled in other 
studies. Thus, in our study, the clinical outcome of patients treated with thiopurines was 
similar to that in previous reports.14,15 
Then, we investigated the efficacy of tacrolimus as maintenance therapy for patients 
with refractory UC in comparison with thiopurines. Our study demonstrated that the 
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proportions of patients intolerant or naive to thiopurines who could maintaine 
steroid-free remission with tacrolimus at 1 year and 3 years were 51.1% and 19.2%, 
respectively (Figure 2), which was similar to that in patients with thiopurines. In 
contrast, the proportions of patients that were refractory to thiopurines at 1 year and 3 
years were 25.0% and 0%, respectively (Figure 2). Relapse-free survival in this group 
was significantly lower than that in thiopurine group. These data suggested that 
administration of tacrolimus with trough levels of 5 to 10 ng/ml as maintenance therapy 
could be an alternative therapy for UC patients intolerant to thiopurines, but might be 
less effective in thiopurine-refractory patients with UC. 
Some reports recommend tacrolimus trough levels of 5 to 10 ng/ml for long-term 
administration to avoid rejection in patients with liver, renal, and small bowel 
transplantation.16,17 Our previous report also showed that the same trough range might 
be optimal for maintaining remission in patients with refractory UC based on its effect 
and safety.9 According to these previous reports, in the study we treated UC patients by 
adjusting the tacrolimus trough levels to 5 to 10 ng/ml in this study. Our data suggested, 
however, that patients with UC who are refractory to thiopurines should be controlled 
with higher trough levels of tacrolimus, a combination of thiopurines and tacrolimus, or 
infliximab. 
One limitation of this study concerns the difference of the induction therapy between 
the tacrolimus group and the thiopurine group. In fact, 82.8% of the patients in the 
tacrolimus group were treated with tacrolimus, while 70% of the patients in the 
thiopurine group received either CS or cytaheresis (Table 4). Therefore, we could not 
exclude the possibility that patients in the thiopurine group had less severe disease than 
those in the tacrolimus group. To solve this issue, additional studies might be required 
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with enrolling patients who received the same induction therapies. 
Finally, we evaluated the adverse effects related to long-term administration of 
tacrolimus therapy. In this study, tremor was the most frequent side effect and severe 
adverse events rarely occurred during tacrolimus maintenance therapy. The frequency 
of drug withdrawal due to side effects was similar between the tacrolimus and 
thiopurine groups, indicating that long-term tacrolimus administration with trough 
levels of 5 to 10 ng/ml could be tolerable in patients with refractory UC. 
In conclusion, our study demonstrated that tacrolimus therapy is a viable alternative for 
maintaining steroid-free remission in UC patients intolerant to thiopurines, although its 




Figure 1. A flow chart of patients in different groups and subgroups.  
 
Figure 2. Relapse-free time intervals of thiopurine-refractory patients and 
thiopurine-naive or thiopurine-intolerant patients in the tacrolimus group and in the 
thiopurine group. The overall cumulative relapse-free survival of thiopurine-refractory 
patients in the tacrolimus group was significantly lower than that in the other two 
groups (log-rank test; p = 0.0104 [vs thiopurine-naive or -intolerant patients] and 
p=0.0008 [vs thiopurine group]). There was no statistical difference between the 
thiopurine-naive or thiopurine-intolerant tacrolimus and thiopurine groups (p=0.5594). 
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Table 1. Modified Truelove Witts severity index (MTWSI) 14   
score 0 1 2 3 4 5 
bowel movement 0-2 3-4 5-6 7-9 >=10  
nocturnal diarrhea no yes     
visible blood in stool 0% <50% >=50% 100%   
abdominal 
tenderness 
none mild moderate severe   
abdominal 
pain/cramping 
none mild moderate severe   
need for 
antidiarrheals 
no yes     
general status perfect very 
good 
good average poor terrible 
fecal incontinence no yes     
Remission category：4 or less 
 
Table 2. Patients’ baseline characteristics in the tacrolimus group and the thiopurine group 
 Tacrolimus group Thiopurine group p-value 
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Sex   0.2913 
Men (%) 12 (50%) 22 (64.7%)  
Women (%) 12 (50%) 12 (35.3%)  
Disease extent   1.0000 
Extensive (%) 17 (70.8%) 24 (70.6%)  
Left-sided (%) 7 (29.2%) 10 (29.4%)  
Response to corticosteroids   0.3428 
Steroid resistance (%)  4 (16.7%) 5 (14.7%)  
Steroid dependence (%) 17 (70.8%) 28 (82.4%)  
Steroid naive (%) 3 (12.5%) 1 (2.9%)  
a Age, b years, and c months are shown. 
Numbers of patients are shown unless specified. 
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Sex   0.4003 
Men (%) 3 (33.3%) 9 (75.0%)  
Women (%) 6 (66.7%) 3 (25.0%)  
Disease extent   1.0000 
Extensive (%) 6 (66.7%) 11 (73.3%)  
Left-sided (%) 3 (33.3%) 4 (26.7%)  
Response to corticosteroids   0.8241 
Steroid resistance (%)  1 (11.1%) 3(20.0%)  
Steroid dependence (%) 7 (77.8%) 10 (66.7%)  
Steroid naive (%) 1 (11.1%) 2 (13.3%)  
a Age, b years, and c months are shown. Numbers of patients are shown unless specified. 
Table 4. Therapies for the induction of remission prior to maintenance therapies 
 Tacrolimus group Thiopurine group 
Prednisolone (%) 1 (3.4%) 20 (50.0%) 
Tacrolimus (%) 24 (82.8%) 11 (27.5%) 
Infliximab (%) 2 (6.9%) 1 (2.5%) 
Cytoapheresis (%) 2 (6.9%) 8 (20.0%) 
Numbers of patients are shown. 
Table 5. Adverse events that developed during tacrolimus treatment 
Adverse events Cases (%) 
Tremor 5 (20.8%) 
Renal function impairment 4 (16.7%) 
(rise in creatinine above 1.3mg/dl)a 
Hot flashes 3 (12.5%) 
Bacterial pnuemonia 1 (4.2%) 
Hyperkalemia 1 (4.2%) 
Epigastralgia 1 (4.2%) 
Headache 1 (4.2%) 
a In one case, tacrolimus withdrawal was not necessary. 
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